Translational research and application of basic biology to clinical trial development in GI cancers.

about

Translational research and application of basic biology to clinical trial development in GI cancers.

Item

http://www.wikidata.org/entity/Q55330265

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Translational research and app ...... ial development in GI cancers.

@en

Translational research and app ...... ial development in GI cancers.

@nl

type

Item

label

Translational research and app ...... ial development in GI cancers.

@en

Translational research and app ...... ial development in GI cancers.

@nl

prefLabel

Translational research and app ...... ial development in GI cancers.

@en

Translational research and app ...... ial development in GI cancers.

@nl

P1476

Translational research and app ...... rial development in GI cancers

@en

P2093

Elizabeth Smyth

http://www.w3.org/2001/XMLSchema#string

Khurum Khan

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

P304

164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/ATM.2018.05.05

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicola Valeri

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29911112

http://www.w3.org/2001/XMLSchema#string

P932

5985276

http://www.w3.org/2001/XMLSchema#string